Recent

% | $
Quotes you view appear here for quick access.

Antares Pharma Inc. Message Board

paras_hemrajani 4 posts  |  Last Activity: May 19, 2016 9:33 PM Member since: Dec 19, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The dates below are for the enrollment and last treatment of the QST safety studies:

    3 November 2014 - Antares Pharma Announces Last Patient Enrolled in Phase 3 Quickshot Study Evaluating Testosterone Deficient Adult Males

    30 October 2015 - Antares Pharma Announces Update to Quickshot Testosterone Program

    EWING, NJ, October 30, 2015 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the
    last patient has completed treatment in the dose-blinded, multiple-dose 52 week Phase 3 study to
    evaluate the efficacy and safety of QuickShot® Testosterone (QS T) administered subcutaneously
    once each week to adult males with hypogonadism.

    3 November 2015 - Antares Pharma Announces Enrollment Complete in Quickshot Supplemental Safety Study QST 15005

    Why have they not announced that the last patient has completed treatment for the 26 week safety study on May 3rd (6 months after the enrollment was completed)? If the 52-week study's start and end announcement dates were timely, what could have held up the timely announcement for the shorter 26-week study? Can anyone provide any insights?

  • Reply to

    current thoughts - answer to stockvader

    by tappyt_2014 May 13, 2016 8:26 AM
    paras_hemrajani paras_hemrajani May 13, 2016 10:58 AM Flag

    I would love to be there, but tied up with a business tip. I would appreciate it if you could relay the following message to Bob & Jim:

    It is imperative that management finds way to significantly reduce expenses or seek a lucrative Otrexup/QST partneship to raise cash. A Secondary offering at current stock prices should would not be prudent.

    Please make morally right and shareholder friendly decisions for the investors that have supported their incomes for the past several years.

  • Reply to

    current thoughts - answer to stockvader

    by tappyt_2014 May 13, 2016 8:26 AM
    paras_hemrajani paras_hemrajani May 13, 2016 8:57 AM Flag

    Tappy - " but I think cash is sufficient to get to profitability without a money raise ".

    I am shocked that you can't even analyze a simple P&L statement and understand that this company will need to raise money in the next 6 months. You are sounding really stupid every time i read your posts. This company has struggled to meet 10% of it s revenue targets for any product introduced. The only potential short-term catalyst that will fade is QST 15-005 results. Maybe worth a trade for it. Long-term this is going to have a R/S and continue to accumulate losses. BTW this is coming from someone who is long.

  • paras_hemrajani by paras_hemrajani May 10, 2016 8:27 PM Flag

    The company is going to need another $50 million before revenues from Makena, Exenatide and QST kick in 1H 2018. Since i don't have have much knowledge of the drug device industry, i was just wondering if anyone can share thoughts if Otrexup can be sold (without selling the company) and if so, would it be able to fetch $50 million? Does anyone think a sales partnership would be considered by a company like HZNP or others?

ATRS
0.9158-0.0323(-3.41%)May 26 4:00 PMEDT